FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
(NASDAQ: MITO) Delayed: 0.32 --0 (-0%)
Previous Close $0.32    52 Week High $ 
Open $10.95    52 Week Low $ 
Day High $0.32    P/E N/A 
Day Low $0.32    EPS $ 
Volume 103,426